Adenovirus-mediated TNF-α gene transfer induces significant tumor regression in mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 1, 1999, Pages 49-57

  Wright, Philip ^a   Braun, Ralph ^b   Babiuk, Lorne ^b   Littel Van Den Hurk, Sylvia Drunen ^b   Moyana, Terence ^a   Zheng, Changyu ^c   Chen, Yue ^d   Xiang, Jim ^a,e  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Saskatoon Cancer Center   (Canada)

Author keywords

Gene gun; Recombinant adenovirus; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; GENE GUN; GENE TARGETING; GENE TRANSFER; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

EID: 0032955729     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.49     Document Type: Article

References (26)

1. Talmadge J, Phillips H, Schneider M. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988; 48:544-550.
2. Shalaby M, Aggrarwal B, Rinderknecht E, et al. Activation of human polymorphonuclear neutrophil function by interferon-gamma and tumor necrosis factor. J Immunol 1985; 135:2069-2073.
3. Robinet E, Branelec D, Termijtelen A, et al. Evidence for tumor necrosis factor involvement in the optimal induction of class I allospecific cytotoxic T cells. J Immunol 1990; 144:4555-4561.
4. Creasey A, Reynolds M and Laird W. Cures and partial regression of murine and human tumors by recombinant human necrosis factor. Cancer Res 1986; 46:5687-5690.
5. Asher A, Mule J, Reichert C, Shiloni E and Rosenberg S. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138:963-974.
6. Freinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor in cancer patients. J Clin Oncol 1986; 6:1328-1334.
7. Moritz T, Niederle N, Baumann J, et al. Phase I study of recombinant human tumor necrosis factor in advanced malignant disease. Cancer Immunol Immunother 1989; 29:144-149.
8. Sherman M, Spriggs D, Arthur K, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metablism. J Clin Oncol 1988; 6:344-354.
9. Creaven P, Plager J, Dupers S, et al. Phase I clinical trial of recombinant human necrosis factor. Cancer Chemother Pharmacol 1987; 20:137-144.
10. Brody S, Jaffee H, Han S, Wersto R, Crystal R. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994; 5:437-447.
11. Chen S, Shine H, Goodman J, Grossman R, Woo A. Gene therapy for brain tumors-regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. PNAS 1994; 91:3054-3057.
12. Neve R. Adnovirus vectors enter the brain. TINS 1993; 16:251-254.
13. Engelhardt J, Simon R, Yang Y, Zepeda M, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther 1993; 4:759.
14. Zabner J, Couture L, Gregory R, Graham S, Smith A, Welsh M. Adenovirus-mediated gene transfer transiently correct the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75:207.
15. Addison C, Braciak T, Ralston R, Muller W, Gauldie J and Graham F. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. PNAS 1995; 92:8522-8526.
16. Toloza E, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A and Economou J. In vivo cancer gene therapy with a recombinant interleukin 2 adenovirus vector. Cancer Gene Ther 1996; 3:11-17.
17. Tanaka F, Abe M, Akiyoshi T, Normura T, Sugimachi K, Kishimoto T, Suzuki T and Okada M. The antihuman tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the IL-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-1343.
18. Zhang J, Hu C, Geng Y, Blatt L and Taylor M. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Therapy 1997; 3:31-38.
19. Yang N and Sun W. Gene gun and other non-viral approaches for cancer gene therapy. Nat Medicine 1995; 1:481-483.
20. Cheng L, Ziegelhoffer P and Yang N. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. PNAS 1993; 90:4455-4459.
21. Sun W, Burkholder J, Sun J, Gulp J, Turner J, Lu X, Pugh T, Ershler W and Yang N. In vivo cytokine gene therapy by gene gun reduces tumor growth in mice. PNAS 1995; 92:2889-2893.
22. Rakhmilevich A, Turner J, Ford M, McCabe D, Sun W, Sondel P, Grota K and Yang N. Gene gun-mediated skin transfection with IL-12 gene results in regression of established primary and metastatic murine tumors. PNAS 1996; 93:6291-6296.
23. Wright P, Moyana T, Zheng C and Xiang J. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor induces significant tumor regression. Cancer Gene Therapy In press, 1998.
24. Cusack J, Spitz F, Nguyen D, Zhang W, Christiano R and Roth J. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Therapy 1996; 3:245-249.
25. Shillitoe E, Noonan S, Hinkle C, Marini F and Kellman R. Transduction of normal and malignant oral epithelium by particle bombardment. Cancer Gene Therapy 1998; 5: 176-182.
26. Hamada K, Alemany R, Zhang W, Hittelman W, Lotan R, Roth J and Mitchell M. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56: 3047-3054.